Performance | China Pharma Holdings' Profit Down 10% Last Year, Dividend 15 Cents

Shijiazhuang Pharmaceutical Group (01093) announced its full-year results for the year ending December 2025. Shareholders’ profit amounted to 3.882 billion RMB, a decrease of 10.3% year-on-year. Earnings per share were 33.98 cents. A final dividend of 15 HK cents per share was declared, an increase of 50% year-on-year; total dividends for the year were 29 HK cents per share, an increase of 11.54%.

During the period, revenue was 26.006 billion RMB, a decrease of 10.35% year-on-year, mainly due to the inclusion of two products, Dumeisu and Jinyouli, in centralized procurement. Gross profit margin slightly declined by 4.4 percentage points to 65.6%.

Looking ahead, the group will continue to leverage the core advantages of its eight major innovation R&D platforms, fully promote key pipeline projects, and aim to achieve critical R&D milestones in 2026. The company will adhere to a clinical demand-oriented approach, actively explore new targets, and expand into emerging fields such as gene therapy, cell therapy, and metabolism. Meanwhile, it will deepen the integration of AI technology in drug R&D, utilizing the drug AI discovery platform to advance the discovery and optimization of innovative candidate drugs, improving R&D efficiency and precision. By empowering innovation through technology, the group aims to transform into an intelligent pharmaceutical enterprise, enhancing R&D capabilities and accelerating the translation of research into results.

In terms of internationalization, the group will promote its global strategy to deepen development, upgrading from “product going abroad” to “platform and technology going abroad.” It will also strengthen strategic cooperation with internationally renowned pharmaceutical companies, further accelerate external licensing, improve overseas operations efficiency, and enhance collaboration with local partners to expand product registration and sales networks.